Special Issue

The Immune Response in Patients after COVID-19 Vaccination

Message from the Guest Editors

The purpose of this Special Issue is to investigate the immunization response, vaccination status, and clinical outcomes in immunocompetent and immunocompromised adults, especially those with sarcoidosis, other interstitial lung diseases or other immunosuppressant statuses, from an immunological or clinical perspective. We look forward to your contributions to this Special Issue, which we hope will contribute to the knowledge regarding this emerging landscape.

Guest Editors

Dr. Ilias C. Papanikolaou Pulmonary Department, Corfu General Hospital, 49100 Corfu, Greece

Dr. Nadera J. Sweiss

Division of Rheumatology, University of Illinois System, Chicago, IL, USA

Deadline for manuscript submissions

closed (31 May 2024)



an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/135467

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines





an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 9.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

